148 related articles for article (PubMed ID: 38461615)
41. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.
Sobas M; Kiladjian JJ; Beauverd Y; Curto-Garcia N; Sadjadian P; Shih LY; Devos T; Krochmalczyk D; Galli S; Bieniaszewska M; Seferynska I; McMullin MF; Armatys A; Spalek A; Waclaw J; Zdrenghea M; Legros L; Girodon F; Lewandowski K; Angona Figueras A; Samuelsson J; Abuin Blanco A; Cony-Makhoul P; Collins A; James C; Kusec R; Lauermannova M; Noya MS; Skowronek M; Szukalski L; Szmigielska-Kaplon A; Wondergem M; Dudchenko I; Gora Tybor J; Laribi K; Kulikowska de Nalecz A; Demory JL; Le Du K; Zweegman S; Besses Raebel C; Skoda R; Giraudier S; Griesshammer M; Harrison CN; Ianotto JC
Blood Adv; 2022 Sep; 6(17):5171-5183. PubMed ID: 35802458
[TBL] [Abstract][Full Text] [Related]
42. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
Kaifie A; Kirschner M; Wolf D; Maintz C; Hänel M; Gattermann N; Gökkurt E; Platzbecker U; Hollburg W; Göthert JR; Parmentier S; Lang F; Hansen R; Isfort S; Schmitt K; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
J Hematol Oncol; 2016 Mar; 9():18. PubMed ID: 26944254
[TBL] [Abstract][Full Text] [Related]
43. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
44. Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.
Bak M; Sørensen TL; Flachs EM; Zwisler AD; Juel K; Frederiksen H; Hasselbalch HC
JAMA Ophthalmol; 2017 Aug; 135(8):835-843. PubMed ID: 28655032
[TBL] [Abstract][Full Text] [Related]
45. Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.
Hultcrantz M; Björkholm M; Dickman PW; Landgren O; Derolf ÅR; Kristinsson SY; Andersson TML
Ann Intern Med; 2018 Mar; 168(5):317-325. PubMed ID: 29335713
[TBL] [Abstract][Full Text] [Related]
46. Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms.
Falanga A; Marchetti M; Schieppati F
Hamostaseologie; 2021 Feb; 41(1):48-57. PubMed ID: 33588455
[TBL] [Abstract][Full Text] [Related]
47. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.
Bang SM; Lee JS; Ahn JY; Lee JH; Hyun MS; Kim BS; Park MR; Chi HS; Kim HY; Kim HJ; Lee MH; Kim H; Won JH; Yoon HJ; Oh DY; Nam EM; Bae SH; Kim BK;
Thromb Haemost; 2009 Mar; 101(3):547-51. PubMed ID: 19277418
[TBL] [Abstract][Full Text] [Related]
48. Leukocytosis and MPNs: Where do we stand?
Coltoff A
Leuk Lymphoma; 2023 Mar; 64(3):564-572. PubMed ID: 36519233
[TBL] [Abstract][Full Text] [Related]
49. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
[TBL] [Abstract][Full Text] [Related]
50. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
51. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
Arachchillage DR; Laffan M
Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
[TBL] [Abstract][Full Text] [Related]
52. Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms.
Lee MW; Yeon SH; Ryu H; Song IC; Lee HJ; Yun HJ; Kim SY; Shin KS; Jo DY
Intern Med; 2022 Dec; 61(23):3483-3490. PubMed ID: 35527026
[TBL] [Abstract][Full Text] [Related]
53. Management of MPN beyond JAK2.
Harrison CN; Garcia NC
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):348-54. PubMed ID: 25696878
[TBL] [Abstract][Full Text] [Related]
54. Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms.
Khan I; Shergill A; Saraf SL; Chen YF; Patel PR; Quigley JG; Peace D; Gordeuk VR; Hoffman R; Rondelli D
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):350-7. PubMed ID: 27052852
[TBL] [Abstract][Full Text] [Related]
55. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms.
Seguro FS; Teixeira LLC; da Rosa LI; da Silva WF; Nardinelli L; Bendit I; Rocha V
J Thromb Thrombolysis; 2020 May; 49(4):667-672. PubMed ID: 31898273
[TBL] [Abstract][Full Text] [Related]
56. [Analysis of risk factors for thromboembolism in patients with JAK2
Zhang YH; Teng GS; Ma JY; Hu X; Du CX; Wang Y; Hu NB; Li YQ; Shao ZH; Bai J
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3652-3657. PubMed ID: 38018064
[No Abstract] [Full Text] [Related]
57. Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Takagi S; Masuoka K; Uchida N; Kurokawa M; Nakamae H; Imada K; Iwato K; Ichinohe T; Atsuta Y; Takami A; Yano S
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2208-2213. PubMed ID: 27667010
[TBL] [Abstract][Full Text] [Related]
58. Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension.
Mulas O; Mola B; Costa A; Pittau F; Mantovani D; Dessì S; Fronteddu A; La Nasa G; Caocci G
Ann Hematol; 2023 Oct; 102(10):2717-2723. PubMed ID: 37603060
[TBL] [Abstract][Full Text] [Related]
59. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
60. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
